Answers are grounded in this paper and cite their sources.
Iron deficiency (ID) with or without anemia is highly prevalent in women, and is commonly caused by abnormal uterine bleeding (AUB; including heavy menstrual bleeding), increased iron requirements during pregnancy, or postpartum hemorrhage (PPH). ID or iron deficiency anemia (IDA) in women of reproductive age has been associated with a substantial burden on quality of life, impaired physical and cognitive functioning, decreased productivity, and increased healthcare costs. The presence of ID/IDA during pregnancy has also been linked to poorer maternal outcomes and fetal developmental impairments, including an increased risk of neurodevelopmental disorders in neonates. Despite the high prevalence of ID/IDA and negative impact on women's health, these conditions are frequently overlooked and undertreated, in part due to the nonspecific nature of symptoms, such as fatigue. There is an increasing body of evidence for the use of intravenous (IV) iron to treat ID/IDA in women. Although efficacy is largely comparable among IV iron formulations when equivalent doses are used, there are factors that distinguish certain IV iron formulations from others. This review aims to discuss available evidence for the treatment of ID/IDA in women with ferric derisomaltose (FDI; a high-dose IV iron formulation), focusing on AUB, pregnancy, and PPH. Based on existing data, FDI represents a clinically-effective option for iron repletion in these contexts, and a low risk of hypersensitivity reactions and hypophosphatemia. There is scope for further research within the field of ID/IDA in women's health to address unmet needs and evidence gaps across the patient care pathway.
No takes yet. Share an insight, caveat, or question.
Murji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: